More Detailed Information
2025 Annual Shareholder Letter HERE.
Form 10-K HERE.
Key Assets and Strategic Developments
- eXoZymes (NASDAQ: EXOZ): MDB holds approximately 4.1 million shares and warrants, valued at approximately
$30 million based onMarch 30, 2026 market prices. The company is advancing cell-free biomanufacturing with large, ownable opportunities and clear commercialization timelines. - Paulex Bio: Closed a
$19 million seed round during 2025, fully funding development. MDB holds approximately 7.1 million shares and warrants. Clinical trial initiation is expected later this year, with an IPO targeted forSeptember 2026 . The beta-cell regeneration platform has multi-billion-dollar potential across Type 1 and Type 2 diabetes. - PatentVest: Advancing toward spin-out as a standalone AI-enhanced IP law firm leveraging a 20-year proprietary patent database, ABS law-firm structure, and agentic AI for patent prosecution — positioned for significant value creation in the rapidly growing legal-tech sector.
- MDB Direct (
Public Ventures clearing platform): In active discussions for a strategic partnership that would realize value from this rare self-clearing asset while dramatically expanding distribution reach into individual-investor channels. - Additional equity positions were earned in HeartBeam and Buda Juice (recorded in 2026) through advisory services, positioning these small, profitable public companies for further growth.
Financial Results
- Annual fixed operating expenses ran at approximately
$10 million for 2025, which includes$4 million investment inMDB Direct/Public Ventures clearing platform and PatentVest. - Net cash used for the full year was approximately
$5.7 million . - At year-end, we also held approximately
$22.3 million in cash, current assets, marketable securities less all liabilities - The Company is targeting improved cost/scale efficiencies as PatentVest and MDB Direct/Public Venture are spun off as independent entities.
Fourth Quarter and Full Year 2025 Results Zoom Webinar at
Investors can register now for the Zoom webinar HERE. The live webinar can also be accessed on the day of the event through MDB’s investor relations website at https://investors.mdb.com/.
About
Founded in 1997,
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond MDB's control. MDB's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in documents that may be filed by MDB from time to time with the
Investor Relations Contact:
IR@mdb.com
Media Contact:
press@mdb.com
Source: 